Did the FDA just leave the door cracked open for PTC’s Duchenne drug after repeated slapdowns?
At first glance, you might conclude that the FDA had simply done what it always does with PTC’s unending battle to gain a green light …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
